AXDX: Accelerate Diagnostics Inc. Market Cap to Revenue

Corporate company logo of Accelerate Diagnostics Inc. (AXDX)

Accelerate Diagnostics (AXDX) business valuation based on P/S demonstrates volatility, amplified by a liquidity shortage and the slow adoption of products within clinics. 0.10 determines the latest valuation metric, which depends on trade barriers and component supply disruptions. However, the implementation of PhenoTest systems to combat bacteremia creates a foundation for the future growth of AXDX market value.

AXDX Accelerate Diagnostics, Inc: P/S Multiple in the range 07/04/2022 - 05/24/2025

Analytical breakdowns for Accelerate Diagnostics, Inc (AXDX)

- stock value and consensus price forecast:
Stock Price acceleratediagnostics.com|AXDX - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Accelerate Diagnostics, Inc|AXDX - Enterprise Value
- book value of equity indicators:
Accounting Value per Share Accelerate Diagnostics|AXDX - Book Capitalization|Market-to-Book Ratio acceleratediagnostics.com|AXDX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Accelerate Diagnostics|AXDX - Long-Term Debt to Capital|Current Liabilities to Capital Accelerate Diagnostics Inc|AXDX - Company Debts|Debt to Net Assets Ratio Accelerate Diagnostics, Inc|AXDX - Company Long-Term Debts|Company Short-Term Debts Accelerate Diagnostics|Intermediate Liquidity Ratio acceleratediagnostics.com
- business earnings and investment ratios data:
AXDX - Net Profit|Expected Net Profit Accelerate Diagnostics|AXDX - Price to Earnings Ratio|Future Price to Earnings Multiple Accelerate Diagnostics Inc.|AXDX - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Accelerate Diagnostics, Inc|AXDX - Operating profit EBITDA|Net earnings per share for the last four quarters Accelerate Diagnostics|AXDX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth acceleratediagnostics.com|AXDX - Earnings growth in current year|Net earnings per one share growth forecast for next year Accelerate Diagnostics
- issuer revenue and sales details:
AXDX - Company Revenue|Company Revenue Forecast acceleratediagnostics.com|AXDX - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Accelerate Diagnostics, Inc
Fundamental company analysis:acceleratediagnostics.com, AXDX
Product sample of Accelerate Diagnostics, Inc.

The P/S multiple compares the market value of Accelerate Diagnostics (AXDX) to its generated revenue, determining the premium the market is willing to pay for every dollar of sales. By analyzing the P/S multiple trend, an investor can assess the effectiveness of the company's transition to a recurring revenue model from the sale of sepsis diagnostic consumables and identify a market undervaluation of the asset in a timely manner.

Competing companies

P/S Multiple agilent.com (A)|P/S Multiple DGX (Quest Diagnostics Incorporated)|ILMN - Market Cap to Revenue|Cologuard - P/S Multiple|Revvity Corp (RVTY) - Market Cap to Revenue|BIO: P/S Multiple|Price to Sales anbio.com (NNNN)|Price-to-Revenue Ratio Sotera Health|Price-to-Revenue Ratio QDEL|P/S Multiple OPK|CDNA - Price to Sales|Price-to-Revenue Ratio Maravai LifeSciences MRVI|Market Capitalization-to-Revenue Ratio FLGT|Standard BioTools - P/S Multiple|CTKB - P/S Multiple|OSUR (OraSure Technologies Inc) - Market Cap to Revenue|XGN: Market Cap to Sales Volume|MDXH (MDxHealth SA) - P/S Multiple|Price to Sales luciddx.com LUCD|Market Cap to Revenue PRE (Prenetics Global)|IMDX (imdxinc.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple TRIB (Trinity Biotech)|PRPH: Market Cap to Revenue Ratio|Ainos, Inc. - P/S Multiple|Price-to-Revenue Coefficient codiagnostics.com CODX|HSCS: P/S Multiple|Biomerica Inc. (BMRA) - P/S Multiple|CDIO (Cardio Diagnostics Holdings Inc.) - P/S Multiple|ONCO - Price-to-Revenue Multiple|Price-to-Revenue Ratio Virax Biolabs Group (VRAX)|bluejaydx.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Aspira Women's Health Inc. AWH|Centogene N.V. (CNTG) - Price to Sales|ENZ - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Fresh2 Group Limited FRES|GENE (gtglabs.com) - Market Cap to Revenue|ME: Market Cap to Sales Volume|PMD (Psychemedics Corporation) - P/S Multiple